Expedition Therapeutics
PrivateLast Round
Series B
Aug 5, 2026
Est. Valuation
$650M
Total Funding Raised
$280M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Expedition Therapeutics operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Series B round in August 2026.
Expedition Therapeutics is a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Expedition Therapeutics Comparables
Compare Expedition Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| cAMPfield Therapeutics | 78% | |
| Alentis Therapeutics | 75% | |
| AirNexis Therapeutics | 73% |
For institutional investors. Book with your work email.
Expedition Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 5, 2026 | ||||
| Series A | Oct 9, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Expedition Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Balyasny Asset Management L.P. | Series A, Series B |
| RA Capital Management | Series B |
| Lake Bleu Capital | Series A |
| Forbion | Series A, Series B |
| Logos Capital | Series A, Series B |
| Novo Holdings | Series B, Series A |
| BVF Partners L.P. | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 3, 2026
Grew 29% QoQ, from 14 to 18 employees.
- Sep 3, 2026
Grew 21% QoQ from 14 to 17 employees.
For institutional investors. Book with your work email.
Expedition Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Expedition Therapeutics's valuation, stock price, and market status.
Is Expedition Therapeutics a public or private company?
Expedition Therapeutics is a private company.
What is the current stock price of Expedition Therapeutics?
Expedition Therapeutics is a private company, so its shares have no public market price. Caplight tracks Expedition Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Expedition Therapeutics worth (valuation)?
Expedition Therapeutics's valuation is estimated at $650.0M based on funding round data.
Can I buy Expedition Therapeutics stock?
Expedition Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Expedition Therapeutics's last funding round?
Expedition Therapeutics's most recent funding round was Series B on August 5, 2026.
Who are the main investors in Expedition Therapeutics?
Key investors in Expedition Therapeutics include Novo Holdings, General Atlantic, Sofinnova Investments.
Will Expedition Therapeutics IPO soon?
No public IPO plans have been announced for Expedition Therapeutics.
How can I track Expedition Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Expedition Therapeutics's shares on secondary markets.